FDA
-
-
-
-
-
-
-
Athersys (ATHX) Announces Successful Type B Meeting with the FDA
-
-
-
-
-
-
-
Athersys Reports First Quarter 2022 Results
-
-
-
-
-
-
-
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
-
-
-
-
-
-
-
Athersys (ATHX) Misses Q2 EPS by 2c
-
-
-
-
-
-
-
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID
-
-
-
-
-
-
-
Athersys (ATHX) Reports FDA Approves Initiation of Pivotal Clinical Trial Evaluating MultiStem Cell Therapy in Patients With COVID-19 Induced ARDS
-
-
-
-
-
-
-
After-Hours Movers 11/26: (ONTX) (TNXP) (BOX) Higher; (ARAV) (ATHX) (GES) Lower (more...)
-
251,634 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All